vs
礼来(RNA)与VALUE LINE INC(VALU)财务数据对比。点击上方公司名可切换其他公司
礼来的季度营收约是VALUE LINE INC的1.5倍($12.5M vs $8.3M),VALUE LINE INC净利率更高(71.4% vs -1398.3%,领先1469.7%),礼来同比增速更快(434.0% vs -7.7%),过去两年礼来的营收复合增速更高(138.5% vs -4.1%)
礼来是总部位于美国印第安纳州印第安纳波利斯的跨国制药企业,在18个国家设有办事处,产品销往全球约125个国家。公司由美国内战时期联邦军退伍军人、药剂师伊莱·礼来于1876年创立,品牌名即取自创始人姓名。
价值线公司是一家总部位于纽约的上市投资研究与金融出版企业,由阿诺德·伯恩哈德于1931年创立。该公司最为人熟知的业务是出版《价值线投资调查》,这份股票分析刊物跟踪覆盖约1700只上市个股的行情与研究。
RNA vs VALU — 直观对比
营收规模更大
RNA
是对方的1.5倍
$8.3M
营收增速更快
RNA
高出441.7%
-7.7%
净利率更高
VALU
高出1469.7%
-1398.3%
两年增速更快
RNA
近两年复合增速
-4.1%
损益表 — Q3 FY2025 vs Q3 FY2026
| 指标 | ||
|---|---|---|
| 营收 | $12.5M | $8.3M |
| 净利润 | $-174.4M | $5.9M |
| 毛利率 | — | — |
| 营业利润率 | -1513.5% | 12.1% |
| 净利率 | -1398.3% | 71.4% |
| 营收同比 | 434.0% | -7.7% |
| 净利润同比 | -117.0% | 14.5% |
| 每股收益(稀释后) | $-1.27 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
RNA
VALU
| Q1 26 | — | $8.3M | ||
| Q4 25 | — | $8.6M | ||
| Q3 25 | $12.5M | $8.6M | ||
| Q2 25 | $3.8M | $8.4M | ||
| Q1 25 | $1.6M | $9.0M | ||
| Q4 24 | $3.0M | $8.8M | ||
| Q3 24 | $2.3M | $8.9M | ||
| Q2 24 | $2.0M | $9.0M |
净利润
RNA
VALU
| Q1 26 | — | $5.9M | ||
| Q4 25 | — | $5.7M | ||
| Q3 25 | $-174.4M | $6.5M | ||
| Q2 25 | $-157.3M | $4.0M | ||
| Q1 25 | $-115.8M | $5.2M | ||
| Q4 24 | $-102.3M | $5.7M | ||
| Q3 24 | $-80.4M | $5.9M | ||
| Q2 24 | $-70.8M | $4.8M |
营业利润率
RNA
VALU
| Q1 26 | — | 12.1% | ||
| Q4 25 | — | 17.7% | ||
| Q3 25 | -1513.5% | 17.4% | ||
| Q2 25 | -4448.7% | 9.9% | ||
| Q1 25 | -8360.9% | 17.4% | ||
| Q4 24 | -4069.6% | 19.7% | ||
| Q3 24 | -4200.9% | 20.8% | ||
| Q2 24 | -4040.4% | 16.5% |
净利率
RNA
VALU
| Q1 26 | — | 71.4% | ||
| Q4 25 | — | 66.4% | ||
| Q3 25 | -1398.3% | 75.1% | ||
| Q2 25 | -4089.3% | 47.1% | ||
| Q1 25 | -7360.0% | 57.6% | ||
| Q4 24 | -3439.5% | 64.3% | ||
| Q3 24 | -3441.7% | 66.3% | ||
| Q2 24 | -3461.8% | 53.1% |
每股收益(稀释后)
RNA
VALU
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $-1.27 | — | ||
| Q2 25 | $-1.21 | — | ||
| Q1 25 | $-0.90 | — | ||
| Q4 24 | $-0.80 | — | ||
| Q3 24 | $-0.65 | — | ||
| Q2 24 | $-0.65 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $350.2M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.9B | $107.8M |
| 总资产 | $2.1B | $151.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势,按日历期对齐
现金及短期投资
RNA
VALU
| Q1 26 | — | $92.5M | ||
| Q4 25 | — | $86.6M | ||
| Q3 25 | $350.2M | $33.7M | ||
| Q2 25 | $243.9M | $67.7M | ||
| Q1 25 | $254.2M | $52.8M | ||
| Q4 24 | $219.9M | $22.3M | ||
| Q3 24 | $370.2M | $30.9M | ||
| Q2 24 | $575.8M | $4.4M |
股东权益
RNA
VALU
| Q1 26 | — | $107.8M | ||
| Q4 25 | — | $105.5M | ||
| Q3 25 | $1.9B | $103.0M | ||
| Q2 25 | $1.2B | $99.7M | ||
| Q1 25 | $1.3B | $99.0M | ||
| Q4 24 | $1.4B | $96.7M | ||
| Q3 24 | $1.5B | $93.9M | ||
| Q2 24 | $1.2B | $90.8M |
总资产
RNA
VALU
| Q1 26 | — | $151.0M | ||
| Q4 25 | — | $147.9M | ||
| Q3 25 | $2.1B | $148.2M | ||
| Q2 25 | $1.4B | $144.5M | ||
| Q1 25 | $1.5B | $143.6M | ||
| Q4 24 | $1.6B | $140.0M | ||
| Q3 24 | $1.6B | $138.6M | ||
| Q2 24 | $1.3B | $136.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $-156.2M | $5.3M |
| 自由现金流经营现金流 - 资本支出 | $-156.9M | — |
| 自由现金流率自由现金流/营收 | -1257.6% | — |
| 资本支出强度资本支出/营收 | 5.7% | 0.0% |
| 现金转化率经营现金流/净利润 | — | 0.89× |
| 过去12个月自由现金流最近4个季度 | $-592.3M | — |
8季度趋势,按日历期对齐
经营现金流
RNA
VALU
| Q1 26 | — | $5.3M | ||
| Q4 25 | — | $3.0M | ||
| Q3 25 | $-156.2M | $5.6M | ||
| Q2 25 | $-199.7M | $20.2M | ||
| Q1 25 | $-124.8M | $6.9M | ||
| Q4 24 | $-99.9M | $3.1M | ||
| Q3 24 | $-65.6M | $4.8M | ||
| Q2 24 | $-65.0M | $17.9M |
自由现金流
RNA
VALU
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $-156.9M | — | ||
| Q2 25 | $-203.0M | $20.1M | ||
| Q1 25 | $-128.6M | $6.8M | ||
| Q4 24 | $-103.8M | $3.0M | ||
| Q3 24 | $-67.3M | $4.8M | ||
| Q2 24 | $-65.5M | $17.9M |
自由现金流率
RNA
VALU
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -1257.6% | — | ||
| Q2 25 | -5277.1% | 239.2% | ||
| Q1 25 | -8174.3% | 75.3% | ||
| Q4 24 | -3491.0% | 34.1% | ||
| Q3 24 | -2881.8% | 53.7% | ||
| Q2 24 | -3204.6% | 199.0% |
资本支出强度
RNA
VALU
| Q1 26 | — | 0.0% | ||
| Q4 25 | — | 0.0% | ||
| Q3 25 | 5.7% | 0.0% | ||
| Q2 25 | 86.9% | 2.1% | ||
| Q1 25 | 238.6% | 1.2% | ||
| Q4 24 | 131.7% | 0.7% | ||
| Q3 24 | 72.9% | 0.0% | ||
| Q2 24 | 26.0% | 0.2% |
现金转化率
RNA
VALU
| Q1 26 | — | 0.89× | ||
| Q4 25 | — | 0.52× | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | — | 5.12× | ||
| Q1 25 | — | 1.33× | ||
| Q4 24 | — | 0.54× | ||
| Q3 24 | — | 0.81× | ||
| Q2 24 | — | 3.75× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图